Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) shares fell 1.05% to $656.12, marking its third consecutive day of losses and closing 20.09% below its 52-week high. Despite the decline, REGN outperformed peers like Amgen and Gilead Sciences on a day when major indices rose modestly. Trading volume remained significantly below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) slid 1.05% to $656.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,543.59 and the Dow Jones Industrial Average rising 0.02% to 52,508.27.
This was the stock's third consecutive day of losses.
Regeneron Pharmaceuticals Inc. closed 20.09% below its 52-week high of $821.11, which the company reached on January 9th.
The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Amgen Inc. (AMGN) fell 1.44% to $355.25, Moderna Inc. (MRNA) rose 0.64% to $67.44, and Gilead Sciences Inc. (GILD) fell 1.04% to $130.04.
Trading volume (472,152) remained 587,391 below its 50-day average volume of 1.1 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 14, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-14-26 1644ET